
Longview PartnersGlobal Equity: MSCI ACWI Benchmark

For the month of: **January** **2025**

Manager Performance Calculations

* Annualized returns

	Last <u>Month</u>	Last <u>3 Months</u>	Last <u>1 Year</u>	Last <u>3 Years*</u>	Last <u>5 Years*</u>
Longview	4.51%	4.08%	13.53%	9.37%	10.06%
MSCI ACWI	3.36%	4.68%	20.72%	8.40%	11.03%

Performance Attribution & Strategy Comments

Among the largest contributors to relative performance were Thermo Fisher, CDW and Medtronic.

Thermo Fisher, the life sciences company, performed well in January following the release of fourth quarter results that were modestly ahead of consensus expectations and positive guidance for 2025. The company expects to achieve 4-5% core organic revenue growth and 6-8% growth in adjusted earnings per share in 2025. The company also expects the wider life sciences tools market to continue to recover in 2025 with a return to growth after the low single digit percentage decline in 2024.

CDW outperformed during January despite little stock specific news and recovered the underperformance experienced in November and December.

Medtronic performed well in January, recovering the post US election underperformance experienced in November and December. Whilst there was limited company specific news, the Centres for Medicare and Medicaid Services (CMS) announced that it is creating a national coverage analysis for Medtronic's Symplicity Spyral renal denervation system for the treatment of hypertension. Whilst there are competing products, such as GLP-1s, this was seen as a positive development for Medtronic given the very large size of the hypertension market and lack of successful treatments currently available.

Some of the largest detractors in January were Booking Holdings, Sysco and Diageo.

Booking Holdings underperformed during January despite little stock specific news. The company remains one of the portfolio's top contributors over the last twelve months and was also the portfolio's top contributor in the fourth quarter of 2024.

Sysco underperformed following the release of its second quarter earnings for the fiscal year ending June 2025. Whilst group results were largely in line with consensus expectations, US case volumes were slightly weaker than expected. The company maintained full year financial guidance of 4-5% revenue growth and 6-7% earnings per share growth but the market appeared to be slightly disappointed by a lack of increase in guidance.

Diageo underperformed during January following a US Surgeon General Advisory calling for cancer risk warnings on alcoholic beverages along with speculation over the potential impact of US tariffs on Mexico and Canada, which would negatively affect Diageo's tequila and Canadian whisky portfolios.

Manager Style Summary

Longview is a "bottom-up" manager, whose process is driven by individual security selection. Country allocations are a by-product of the stock selection process, which drives the portfolio country over and under weights, and is unconstrained by the index weights. The portfolio holds 30-35 securities at a time, and stocks are equally weighted. It is a concentrated global equity portfolio, and as such, may experience more volatility relative to the market.

Longview Partners

Global Equity: MSCI ACWI Benchmark

Portfolio Guideline Compliance

Portfolio Guideline:	Longview	Min	Max	Compliance
B3. Security position <= 5% of the account @ purchase				Yes
B4. Number of issues	30.0	30	35	ok
B5. Normal Regional Exposures (* benchmark +/- min/max):				
United States & Canada	83%	35%	80%	check
Europe incl U.K.	17%	20%	50%	check
Japan	0%	0%	20%	ok
Emerging Markets	0%	0%	15%	ok
Non-Index Countries	0%	0%	10%	ok
Total	100%			
B6. Normal Global Portfolio Characteristics				
Median Mkt Cap (in billions)	116,457	\$10		ok
Price/Earnings (Trailing)	27.1	10	17	check
Dividend Yield	1%	0.5%	2.0%	ok
Price/Cash Flow (Trailing)	18.5	10	14	check
C1. No executed forward w/o a corresponding securities position.				Yes
C2. Foreign Currency (cash or cash equiv) <= 8% of Account value				Yes
F2. Brokerage commissions not to exceed \$0.06/share for U.S. equities				Yes
F3. Annual turnover	12%	25%	50%	check
The portfolio is in compliance with all other aspects of the Portfolio Guidelines			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	

Manager Explanations for Deviations from Portfolio Guidelines

B5. Regional Exposures: The output of our investment process is a concentrated, yet diversified, portfolio of typically 35 names, unconstrained by geography or sector.

B6. Price/Earnings: Price/Earnings is not targeted and stood at 27.1 in January.

B6. Price/Cash Flow: Price/Cash Flow is not targeted and stood at 18.5 in January.

F3. Annual Turnover: We do not target a specific level of turnover. Annual turnover is calculated on a rolling 12 month period and includes client flows.

Total Firm Assets Under Management (\$m) as of:

Qtr 1 \$ 16,803

Organizational/Personnel Changes

There were no changes to the investment team in January.

Account Turnover

Gained:	Number of Accounts:	0	(\$m):	\$ -
Lost:	Number of Accounts:	0	(\$m):	\$ -
	Reason(s):			